Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 5
2009 4
2010 1
2011 2
2012 6
2013 2
2014 3
2015 2
2016 3
2017 6
2018 6
2019 3
2020 5
2021 4
2022 1
2023 2
2024 2
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA; RUBY Investigators. Mirza MR, et al. N Engl J Med. 2023 Jun 8;388(23):2145-2158. doi: 10.1056/NEJMoa2216334. Epub 2023 Mar 27. N Engl J Med. 2023. PMID: 36972026 Clinical Trial.
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.
Vergote I, González-Martín A, Fujiwara K, Kalbacher E, Bagaméri A, Ghamande S, Lee JY, Banerjee S, Maluf FC, Lorusso D, Yonemori K, Van Nieuwenhuysen E, Manso L, Woelber L, Westermann A, Covens A, Hasegawa K, Kim BG, Raimondo M, Bjurberg M, Cruz FM, Angelergues A, Cibula D, Barraclough L, Oaknin A, Gennigens C, Nicacio L, Teng MSL, Whalley E, Soumaoro I, Slomovitz BM; innovaTV 301/ENGOT-cx12/GOG-3057 Collaborators. Vergote I, et al. N Engl J Med. 2024 Jul 4;391(1):44-55. doi: 10.1056/NEJMoa2313811. N Engl J Med. 2024. PMID: 38959480 Clinical Trial.
Effect of sleep deprivation on the human metabolome.
Davies SK, Ang JE, Revell VL, Holmes B, Mann A, Robertson FP, Cui N, Middleton B, Ackermann K, Kayser M, Thumser AE, Raynaud FI, Skene DJ. Davies SK, et al. Among authors: ang je. Proc Natl Acad Sci U S A. 2014 Jul 22;111(29):10761-6. doi: 10.1073/pnas.1402663111. Epub 2014 Jul 7. Proc Natl Acad Sci U S A. 2014. PMID: 25002497 Free PMC article. Clinical Trial.
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.
de Bono JS, Concin N, Hong DS, Thistlethwaite FC, Machiels JP, Arkenau HT, Plummer R, Jones RH, Nielsen D, Windfeld K, Ghatta S, Slomovitz BM, Spicer JF, Yachnin J, Ang JE, Mau-Sørensen PM, Forster MD, Collins D, Dean E, Rangwala RA, Lassen U. de Bono JS, et al. Among authors: ang je. Lancet Oncol. 2019 Mar;20(3):383-393. doi: 10.1016/S1470-2045(18)30859-3. Epub 2019 Feb 8. Lancet Oncol. 2019. PMID: 30745090 Clinical Trial.
Assessment of early response to neoadjuvant chemotherapy in multi-site high-grade serous ovarian cancer using hyperpolarized-13C MRI.
Beer L, Bura V, Ursprung S, Woitek R, McLean MA, Ang JE, Jimenez-Linan M, Gill AB, Kaggie J, Locke M, Frary A, Field-Rayner J, Patterson I, Reinius M, Graves MJ, Deen S, Funingana G, Rundo L, Priest A, Aloj L, Manavaki R, Mendichovszky IA, Robb F, Schulte RF, Couturier DL, D'Santos CS, Franklin V, Kishore K, Allajbeu I, Sauer C, Gallagher FA, Brindle KM, Brenton JD, Sala E. Beer L, et al. Among authors: ang je. EJNMMI Res. 2025 Apr 17;15(1):40. doi: 10.1186/s13550-025-01219-5. EJNMMI Res. 2025. PMID: 40246745 Free PMC article.
Ovarian cancer: can we reverse drug resistance?
Tan DS, Ang JE, Kaye SB. Tan DS, et al. Among authors: ang je. Adv Exp Med Biol. 2008;622:153-67. doi: 10.1007/978-0-387-68969-2_13. Adv Exp Med Biol. 2008. PMID: 18546626 Review. No abstract available.
Belzutifan for Advanced Pheochromocytoma or Paraganglioma.
Jimenez C, Andreassen M, Durand A, Moog S, Hendifar A, Welin S, Spada F, Sharma R, Wolin E, Ruether J, Garcia-Carbonero R, Fassnacht M, Capdevila J, Del Rivero J, Iliopoulos O, Huillard O, Jang R, Mai K, Artamonova E, Hallqvist A, Else T, Odeleye-Ajakaye A, Gozman A, Naik GS, Berruti A; LITESPARK-015 Investigators. Jimenez C, et al. N Engl J Med. 2025 Nov 20;393(20):2012-2022. doi: 10.1056/NEJMoa2504964. Epub 2025 Oct 18. N Engl J Med. 2025. PMID: 41124218 Clinical Trial.
Systematic Review and Meta-Analysis: Early Irritability as a Transdiagnostic Neurodevelopmental Vulnerability to Later Mental Health Problems.
Finlay-Jones AL, Ang JE, Brook J, Lucas JD, MacNeill LA, Mancini VO, Kottampally K, Elliott C, Smith JD, Wakschlag LS. Finlay-Jones AL, et al. Among authors: ang je. J Am Acad Child Adolesc Psychiatry. 2024 Feb;63(2):184-215. doi: 10.1016/j.jaac.2023.01.018. Epub 2023 Feb 28. J Am Acad Child Adolesc Psychiatry. 2024. PMID: 36863413 Free PMC article.
50 results